What were the top pharma news stories as of September 2026?

September’s pharmaceutical landscape was shaped by expanded federal drug-pricing policies, major immunology deals, and growing legal scrutiny around blockbuster therapies. The Trump administration expanded its “most-favored-nation” pricing campaign, Eli Lilly acquired Merida Biosciences for $2.88 billion, and GLP-1 drugmakers faced mounting litigation over rare vision-loss risks. The Fullintel Hub keeps stakeholders informed as these developments unfold and continue to shape the pharmaceutical landscape. 

September 2026 Pharma News Breakdown

White House Strikes New Drug-Pricing Deals

What do the widening drug-pricing deals signal for federal healthcare strategy?

On August 31, the White House unveiled a fresh round of voluntary  Most-Favored-Nation (MFN) drug-pricing deals, this time reaching beyond the industry giants to midsize and biotech drugmakers. Under the framework, participating companies agree to bring U.S. prices for selected single-source medicines in line with the lower prices paid abroad, and in return they receive policy exemptions and greater regulatory predictability. Less than three weeks later, the administration expanded the approach further.

What it means:

• The latest round brought growing biotech manufacturers into the fold, with Astellas, BeOne, BridgeBio, CSL, Sun Pharma and UCB among the new signatories, extending price-matching commitments into specialty therapies.
• The White House said the voluntary pacts would deliver immediate net price reductions for high-cost drugs without the need for new legislation from Congress.
• Critics and policy analysts argued that the secretive, company-by-company negotiations made it impossible to judge how much patients or taxpayers would actually save, and warned that the deals might not deliver lasting structural relief.
• On September 18, President Trump extended MFN pricing to Medicaid programs in all 50 states, Washington, D.C. and Puerto Rico. The White House projected nearly $65 billion in Medicaid savings over a decade, although experts cautioned that the figure could not be verified because the terms of the underlying deals remain private.
• The strategy reflects a broader push to use executive power to reshape how drugs are priced at home, with the midterm elections now weeks away. 

Media takeaway: 

Sentiment was mixed overall but shifted more positive toward the end of the month. “Love” and “Wow” reactions became more prominent as supporters praised lower government drug spending, while a notable “Angry” and “Sad” contingent continued to question the lack of transparency, the absence of binding legislation, and potential impacts on global drug supply chains.

Eli Lilly Inks $2.88 Billion Merida Buyout for Autoimmune Drugs Against Rogue Antibodies  

What does Eli Lilly’s acquisition of Merida Biosciences signal for immunology and pipeline diversification?

Eli Lilly is putting its obesity windfall to work again. On August 31, the company agreed to acquire Merida Biosciences for up to $2.875 billion in cash and milestone payments, gaining an antibody-engineering platform designed to clear out the rogue autoantibodies that drive disease while leaving the rest of the immune system intact.

What it means:

• The deal secures lead asset MER511, a Phase 1 therapy that targets the pathogenic antibodies behind Graves’ disease and thyroid eye disease.
• Merida’s broader preclinical pipeline gives Lilly a foothold in IgE-driven allergic conditions such as food allergies and asthma, as well as in autoimmune kidney disease.
• The acquisition is the latest in a steady run of platform buys as Lilly channels its GLP-1 revenues into efforts to diversify beyond obesity.

Media takeaway: 

“Love” and “Wow” reactions dominated as commenters welcomed a targeted alternative to broad immunosuppression. Skeptical engagement was minimal, primarily raising questions around Phase 1 clinical timelines and execution risks.

Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss 

What does the growing NAION litigation signal for GLP-1 safety and product liability?

Patients have filed lawsuits against Novo Nordisk and Eli Lilly, alleging that GLP-1 drugs including Ozempic, Wegovy, Mounjaro, and Zepbound can trigger non-arteritic anterior ischemic optic neuropathy (NAION), a rare so-called eye stroke in which reduced blood flow to the optic nerve causes sudden and often permanent vision loss. More than 200 cases have now been consolidated in federal multidistrict litigation in the Eastern District of Pennsylvania, where plaintiffs claim the companies failed to warn patients and doctors about the risk.

What it means:

• At the heart of the case are allegations that U.S. labels carry no explicit NAION warning, mentioning only temporary blurred vision and the progression of diabetic retinopathy.

• Plaintiffs point to observational studies that found a higher relative risk of NAION among semaglutide users than among patients on other treatments.

• Novo Nordisk and Eli Lilly have called the claims meritless, arguing that causation has not been proven and citing real-world data and meta-analyses that found no significant overall increase in risk.

• Regulators abroad have already acted on very rare post-marketing reports of NAION linked to semaglutide, with the EU and Australia adding the possible risk to product labels. The FDA has not yet followed, leaving the door open to a future U.S. label change.

Media takeaway: 

Social media discussions centered on product liability, failure-to-warn claims, and safety surveillance in popular metabolic therapies. Online reactions leaned heavily negative, dominated by “Angry” and “Sad” responses over fears of permanent vision loss and frustration regarding drug risk disclosure.